Stockreport

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Entrada Therapeutics, Inc.  (TRDA) 
PDF – Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual C [Read more]